Page 1803 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 104 Indications and Outcomes of Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies in Adults 1607

14. Bortin MM, Truitt RL, Rimm AA, et al: Graft-versus-leukaemia reactivity 28. Baccarani M, Deininger MW, Rosti G, et al: European LeukemiaNet
induced by alloimmunisation without augmentation of graft-versus-host recommendations for the management of chronic myeloid leukemia:
reactivity. Nature 281(5731):490–491, 1979. 2013. Blood 122(6):872–884, 2013.
15. Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia 29. Dreger P, Corradini P, Kimby E, et al: Indications for allogeneic stem cell
reactions after bone marrow transplantation. Blood 75(3):555–562, transplantation in chronic lymphocytic leukemia: the EBMT transplant
1990. consensus. Leukemia 21(1):12–17, 2007.
16. Leung W, Iyengar R, Turner V, et al: Determinants of antileukemia 30. Oliansky DM, Czuczman M, Fisher RI, et al: The role of cytotoxic
effects of allogeneic NK cells. J Immunol 172(1):644–650, 2004. therapy with hematopoietic stem cell transplantation in the treatment of
17. Cooley S, Weisdorf DJ, Guethlein LA, et al: Donor selection for natural diffuse large B cell lymphoma: update of the 2001 evidence-based review.
killer cell receptor genes leads to superior survival after unrelated trans- Biol Blood Marrow Transplant 17(1):20–47.e30, 2011.
plantation for acute myelogenous leukemia. Blood 116(14):2411–2419, 31. Oliansky DM, Gordon LI, King J, et al: The role of cytotoxic therapy
2010. with hematopoietic stem cell transplantation in the treatment of follicu-
18. Horan JT, Logan BR, Agovi-Johnson MA, et al: Reducing the risk lar lymphoma: an evidence-based review. Biol Blood Marrow Transplant
for transplantation-related mortality after allogeneic hematopoietic 16(4):443–468, 2010.
cell transplantation: how much progress has been made? J Clin Oncol 32. Zelenetz AD, Wierda WG, Abramson JS, et al: Non-Hodgkin’s lympho-
29(7):805–813, 2011. mas, version 1.2013. J Natl Compr Canc Netw 11(3):257–272, quiz 273,
19. Sorror ML, Maris MB, Storb R, et al: Hematopoietic cell transplantation 2013.
(HCT)-specific comorbidity index: a new tool for risk assessment before 33. Lim Z, Brand R, Martino R, et al: Allogeneic hematopoietic stem-
allogeneic HCT. Blood 106(8):2912–2919, 2005. cell transplantation for patients 50 years or older with myelodysplastic
20. Armand P, Kim HT, Logan BR, et al: Validation and refinement of syndromes or secondary acute myeloid leukemia. J Clin Oncol
the Disease Risk Index for allogeneic stem cell transplantation. Blood 28(3):405–411, 2010.
123(23):3664–3671, 2014. 34. Crawley C, Iacobelli S, Björkstrand B, et al: Reduced-intensity con-
21. Eapen M, Rocha V: Principles and analysis of hematopoietic stem cell ditioning for myeloma: lower nonrelapse mortality but higher relapse
transplantation outcomes: the physician’s perspective. Lifetime Data Anal rates compared with myeloablative conditioning. Blood 109:3588–3594,
14(4):379–388, 2008. 2007.
22. Socie G, Stone JV, Wingard JR, et al: Long-term survival and late deaths 35. Martino R, Iacobelli S, Brand R, et al: Retrospective comparison of
after allogeneic bone marrow transplantation. Late Effects Working reduced-intensity conditioning and conventional high-dose conditioning
Committee of the International Bone Marrow Transplant Registry. N for allogeneic hematopoietic stem cell transplantation using HLAidenti-
Engl J Med 341(1):14–21, 1999. cal sibling donors in myelodysplastic syndromes. Blood 108:836–846,
23. Dohner H, Estey EH, Amadori S, et al: Diagnosis and management 2006.
of acute myeloid leukemia in adults: recommendations from an inter- 36. Dreger P, Brand R, Milligan D, et al: Reduced-intensity conditioning
national expert panel, on behalf of the European LeukemiaNet. Blood lowers treatment-related mortality of allogeneic stem cell transplanta-
115(3):453–474, 2010. tion for chronic lymphocytic leukemia: a population-matched analysis.
24. Hubel K, Weingart O, Naumann F, et al: Allogeneic stem cell transplant Leukemia 19:1029–1033, 2005.
in adult patients with acute myelogenous leukemia: a systematic analysis 37. Sureda A, Robinson S, Canals C, et al: Reduced-intensity conditioning
of international guidelines and recommendations. Leuk Lymphoma compared with conventional allogeneic stem-cell transplantation in
52(3):444–457, 2011. relapsed or refractory Hodgkin’s lymphoma: An analysis from the Lym-
25. Goldstone AH, Richards SM, Lazarus HM, et al: In adults with standard- phoma Working Party of the European Group for Blood and Marrow
risk acute lymphoblastic leukemia, the greatest benefit is achieved from Transplantation. J Clin Oncol 26:455–462, 2008.
a matched sibling allogeneic transplantation in first complete remission, 38. Hari P, Carreras J, Zhang MJ, et al: Allogeneic transplants in follicular
and an autologous transplantation is less effective than conventional lymphoma: higher risk of disease progression after reduced-intensity
consolidation/maintenance chemotherapy in all patients: final results of compared to myeloablative conditioning. Biol Blood Marrow Transplant
the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 14:236–245, 2008.
111(4):1827–1833, 2008. 39. Mohty M, Labopin M, Volin L, et al: Reduced-intensity versus conven-
26. Pidala J, Djulbegovic B, Anasetti C, et al: Allogeneic hematopoietic cell tional myeloablative conditioning allogeneic stem cell transplantation
transplantation for adult acute lymphoblastic leukemia (ALL) in first for patients with acute lymphoblastic leukemia: A retrospective study
complete remission. Cochrane Database Syst Rev (10):CD008818, 2011. from the European Group for Blood and Marrow Transplantation. Blood
doi(10):CD008818. 116:4439–4443, 2010.
27. Oliansky DM, Larson RA, Weisdorf D, et al: The role of cytotoxic 40. Luger SM, Ringdén O, Zhang MJ, et al: Similar outcomes using
therapy with hematopoietic stem cell transplantation in the treatment of myeloablative vs. reduced-intensity allogeneic transplant prepara-
adult acute lymphoblastic leukemia: update of the 2006 evidence-based tive regimens for AML or MDS. Bone Marrow Transplant 47:203,
review. Biol Blood Marrow Transplant 18(1):16–17, 2012. 2012.